» Articles » PMID: 39217172

Antibodies Utilizing VL6-57 Light Chains Target a Convergent Cryptic Epitope on SARS-CoV-2 Spike Protein and Potentially Drive the Genesis of Omicron Variants

Abstract

Continued evolution of SARS-CoV-2 generates variants to challenge antibody immunity established by infection and vaccination. A connection between population immunity and genesis of virus variants has long been suggested but its molecular basis remains poorly understood. Here, we identify a class of SARS-CoV-2 neutralizing public antibodies defined by their shared usage of VL6-57 light chains. Although heavy chains of diverse genotypes are utilized, convergent HCDR3 rearrangements have been observed among these public antibodies to cooperate with germline VL6-57 LCDRs to target a convergent epitope defined by RBD residues S371-S373-S375. Antibody repertoire analysis identifies that this class of VL6-57 antibodies is present in SARS-CoV-2-naive individuals and is clonally expanded in most COVID-19 patients. We confirm that Omicron-specific substitutions at S371, S373 and S375 mediate escape of antibodies of the VL6-57 class. These findings support that this class of public antibodies constitutes a potential immune pressure promoting the introduction of S371L/F-S373P-S375F in Omicron variants. The results provide further molecular evidence to support that antigenic evolution of SARS-CoV-2 is driven by antibody mediated population immunity.

Citing Articles

The Compensatory Effect of S375F on S371F Is Vital for Maintaining the Infectivity of SARS-CoV-2 Omicron Variants.

Liu S, Liu P, Lu Q, Shen Y, Zhang L, Liang Z J Med Virol. 2025; 97(3):e70242.

PMID: 40062404 PMC: 11891949. DOI: 10.1002/jmv.70242.


Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic.

Furnon W, Cowton V, De Lorenzo G, Orton R, Herder V, Cantoni D Nat Microbiol. 2025; 10(1):77-93.

PMID: 39753670 PMC: 11726466. DOI: 10.1038/s41564-024-01878-5.


Structural Immunology of SARS-CoV-2.

Yuan M, Wilson I Immunol Rev. 2024; 329(1):e13431.

PMID: 39731211 PMC: 11727448. DOI: 10.1111/imr.13431.

References
1.
Carabelli A, Peacock T, Thorne L, Harvey W, Hughes J, Peacock S . SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3):162-177. PMC: 9847462. DOI: 10.1038/s41579-022-00841-7. View

2.
Markov P, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis N . The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023; 21(6):361-379. DOI: 10.1038/s41579-023-00878-2. View

3.
Harvey W, Carabelli A, Jackson B, Gupta R, Thomson E, Harrison E . SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021; 19(7):409-424. PMC: 8167834. DOI: 10.1038/s41579-021-00573-0. View

4.
Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C . SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022; 185(3):467-484.e15. PMC: 8723827. DOI: 10.1016/j.cell.2021.12.046. View

5.
Liu L, Iketani S, Guo Y, Chan J, Wang M, Liu L . Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022; 602(7898):676-681. DOI: 10.1038/s41586-021-04388-0. View